Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Ma

Showing results (81-90 of 357) with videos related to

Pageof 36
Sort By:
Journal of Medical Imaging and Radiation Oncology|June 1, 2022
Adjuvant nodal field radiation in resected Stage III melanoma: A single-centre retrospective study in Christchurch, New ZealandTian Weng Leong, George McCook, Christopher Ma Frampton, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 18, 2020
Endoscopic Assessment of Inflammatory Bowel Disease Activity in Clinical TrialsReena Khanna, Christopher Ma, Vipul Jairath, et al.
Crohn'S & Colitis 360|July 1, 2024
Differences Between the 2016 and 2022 Food and Drug Administration Guidance-Implications for Design and Interpretation of Clinical Trials in Ulcerative ColitisJurij Hanzel, Christopher Ma, Laurent Peyrin-Biroulet, et al.
Advances in Therapy|June 27, 2023
Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn's DiseaseMarla Dubinsky, Christopher Ma, Jenny Griffith, et al.
Gastroenterology|May 10, 2026
EFFECTIVENESS OF RISANKIZUMAB AFTER USTEKINUMAB FAILURE IN CROHN'S DISEASE: A MULTICENTER RETROSPECTIVE COHORT STUDYShiva Mehta-Dhand, Nima Hamidi, Ashley N Clarke, et al.
Inflammatory Bowel Diseases|February 1, 2020
Vedolizumab Induced Clinical, Endoscopic, and Histological Improvement in Common Variable Immunodeficiency Disease-associated Intestinal EnteropathyHisham Javed Akhtar, Bharat Markandey, Christopher Ma, et al.
Expert Review of Gastroenterology & Hepatology|February 23, 2019
Update on C-reactive protein and fecal calprotectin: are they accurate measures of disease activity in Crohn's disease?Christopher Ma, Robert Battat, Claire E Parker, et al.
The New Zealand Medical Journal|December 2, 2016
The scratch test for identifying the lower liver edge is at least as accurate as percussion and is significantly more effective for young trainees-a randomised comparative trialAlexander Huelsen, Jesse Fischer, Justin Hegarty, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 30, 2018
Early Initiation of Tumor Necrosis Factor Antagonist-Based Therapy for Patients With Crohn's Disease Reduces Costs Compared With Late InitiationCandace L Beilman, Erin Kirwin, Christopher Ma, et al.
Drugs|August 28, 2021
Correction to: Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel DiseaseJurij Hanzel, Christopher Ma, Niels Vande Casteele, et al.
Pageof 36

Showing results (81-90 of 357) with videos related to

Sort By:
Pageof 36
Journal of Medical Imaging and Radiation Oncology|June 1, 2022
Adjuvant nodal field radiation in resected Stage III melanoma: A single-centre retrospective study in Christchurch, New ZealandTian Weng Leong, George McCook, Christopher Ma Frampton, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 18, 2020
Endoscopic Assessment of Inflammatory Bowel Disease Activity in Clinical TrialsReena Khanna, Christopher Ma, Vipul Jairath, et al.
Crohn'S & Colitis 360|July 1, 2024
Differences Between the 2016 and 2022 Food and Drug Administration Guidance-Implications for Design and Interpretation of Clinical Trials in Ulcerative ColitisJurij Hanzel, Christopher Ma, Laurent Peyrin-Biroulet, et al.
Advances in Therapy|June 27, 2023
Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn's DiseaseMarla Dubinsky, Christopher Ma, Jenny Griffith, et al.
Gastroenterology|May 10, 2026
EFFECTIVENESS OF RISANKIZUMAB AFTER USTEKINUMAB FAILURE IN CROHN'S DISEASE: A MULTICENTER RETROSPECTIVE COHORT STUDYShiva Mehta-Dhand, Nima Hamidi, Ashley N Clarke, et al.
Inflammatory Bowel Diseases|February 1, 2020
Vedolizumab Induced Clinical, Endoscopic, and Histological Improvement in Common Variable Immunodeficiency Disease-associated Intestinal EnteropathyHisham Javed Akhtar, Bharat Markandey, Christopher Ma, et al.
Expert Review of Gastroenterology & Hepatology|February 23, 2019
Update on C-reactive protein and fecal calprotectin: are they accurate measures of disease activity in Crohn's disease?Christopher Ma, Robert Battat, Claire E Parker, et al.
The New Zealand Medical Journal|December 2, 2016
The scratch test for identifying the lower liver edge is at least as accurate as percussion and is significantly more effective for young trainees-a randomised comparative trialAlexander Huelsen, Jesse Fischer, Justin Hegarty, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 30, 2018
Early Initiation of Tumor Necrosis Factor Antagonist-Based Therapy for Patients With Crohn's Disease Reduces Costs Compared With Late InitiationCandace L Beilman, Erin Kirwin, Christopher Ma, et al.
Drugs|August 28, 2021
Correction to: Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel DiseaseJurij Hanzel, Christopher Ma, Niels Vande Casteele, et al.
Pageof 36